Drug Transporter (DT) Information

General Information of DT
DT ID DTD0151
Gene Name SLC22A4
Protein Name Organic cation/carnitine transporter 1
Gene ID
6583
UniProt ID
Q9H015
TCDB ID
2.A.1.19.2
3D Structure

Modelled DT Structure

Method: multi-sequence alignment based machine learning

Detail: Structure Info

Synonyms DFNB60; ET transporter; ETT; Ergothioneine transporter; OCTN1; SLC22A4; Solute carrier family 22 member 4; UT2H
DT Family Major Facilitator Superfamily (MFS)
Organic Cation Transporter (OCT) Family
Tissue Specificity Widely expressed. Highly expressed in wholeblood, bone marrow, trachea and fetal liver. Weakly expressed inkidney, skeletal muscle, prostate, lung, pancreas, placenta,heart, uterus, spleen and spinal cord. Highly expressed inintestinal cell types affected by Crohn disease, includingepithelial cells. Expressed in CD68 macrophage and CD43 T-cellsbut not in CD20 B-cells. Predominantly expressed in CD14 cells inperipheral blood mononuclear cells.
Function This sodium-ion dependent transporter mediates the tranport of carnitine and sodium-ion. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. A key substrate of this transporter seems to be ergothioneine (ET).
Disease(s) Malaria [ICD-11: 1F40]
Nutritional deficiency [ICD-11: 5B7Z]
Obstructive lung diseases [ICD-11: CA22.Z]
Partial seizures [ICD-11: 8A68.0]
Endogenous Substrate(s) Ergothioneine
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(α) Microbiota Influence of This DT
Microbiota Influence (MBI)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

Structural Variability Data of This DT (VARIDT 2.0)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:            6 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Cytarabine
 Approved Drug Info Acute myeloid leukemia 2A60 [1]
Gabapentin
 Approved Drug Info Partial seizures 8A68.0 [2]
Ipratropium
 Approved Drug Info Obstructive lung diseases CA22.Z [3]
L-carnitine
 Approved Drug Info Nutritional deficiency 5B7Z [4]
Quinine
 Approved Drug Info Malaria 1F40 [5]
Verapamil
 Approved Drug Info High blood pressure BA00 [5]

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Tetraethylammonium
 Phase 2 Drug Info Hyperlipidaemia 5C8Z [6]

Endogenous Metabolites (EMs) Handled by This DT

 Endogenous Metabolites (EMs)

 Click to Show/Hide the Full List of EMs:            1 EMs in Total
EM Name PubChem CID Detail Experimental Material Ref
Carnitine
288
EM Info Identified using oocytes of xenopus laevis-OCTN1 [7]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Ipratropium Approved Drug Info Human embryonic kidney cells (HEK293)-OCTN1 Km = 444 microM [3]

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            3 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Tetraethylammonium Phase 2 Drug Info Human embryonic kidney cells (HEK293)-OCTN1 Km = 436 microM [5]
Tetraethylammonium Phase 2 Drug Info Human embryonic kidney cells (HEK293)-OCTN1 Km = 1800 microM [6]
Tetraethylammonium Phase 2 Drug Info Oocytes-OCTN1 Km = 195 microM [5]
References
1 OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Res. 2017 Apr 15;77(8):2102-2111.
2 Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther. 2008 Mar;83(3):416-21.
3 Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95.
4 Spontaneous development of intestinal and colonic atrophy and inflammation in the carnitine-deficient jvs (OCTN2(-/-)) mice. Mol Genet Metab. 2007 Dec;92(4):315-24.
5 Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73.
6 Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). Pharmacogenet Genomics. 2007 Sep;17(9):773-82.
7 Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet. 2004 May;36(5):471-5.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.